ATE435906T1 - Verfahren zur reinigung von viren - Google Patents

Verfahren zur reinigung von viren

Info

Publication number
ATE435906T1
ATE435906T1 AT06126383T AT06126383T ATE435906T1 AT E435906 T1 ATE435906 T1 AT E435906T1 AT 06126383 T AT06126383 T AT 06126383T AT 06126383 T AT06126383 T AT 06126383T AT E435906 T1 ATE435906 T1 AT E435906T1
Authority
AT
Austria
Prior art keywords
cleaning viruses
adenovirus
viruses
cleaning
preparation
Prior art date
Application number
AT06126383T
Other languages
English (en)
Inventor
Miranda Weggeman
Corven Emile Joannes Josephus Maria Van
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34878416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE435906(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE435906T1 publication Critical patent/ATE435906T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06126383T 2004-02-23 2005-02-21 Verfahren zur reinigung von viren ATE435906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2004050190 2004-02-23

Publications (1)

Publication Number Publication Date
ATE435906T1 true ATE435906T1 (de) 2009-07-15

Family

ID=34878416

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06126383T ATE435906T1 (de) 2004-02-23 2005-02-21 Verfahren zur reinigung von viren

Country Status (13)

Country Link
US (2) US20070207461A1 (de)
EP (2) EP1780269B1 (de)
JP (1) JP2007522814A (de)
KR (1) KR101211329B1 (de)
CN (2) CN1922308A (de)
AT (1) ATE435906T1 (de)
AU (1) AU2005214090B2 (de)
CA (1) CA2555412C (de)
DE (1) DE602005015332D1 (de)
DK (1) DK1780269T3 (de)
ES (1) ES2329607T3 (de)
NZ (1) NZ548495A (de)
WO (1) WO2005080556A2 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000326A1 (en) 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1780269B1 (de) 2004-02-23 2009-07-08 Crucell Holland B.V. Verfahren zur Reinigung von Viren
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
WO2007052163A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
DK2195418T3 (da) 2007-10-02 2013-03-18 Ptc Phage Technology Ct Gmbh Fremgangsmåde og system til rensning af bakteriofager beregnet til bakteriofagterapi i industriel skala
JP2011511640A (ja) * 2008-02-12 2011-04-14 サノフィ パストゥール リミテッド ポックス・ウイルスの精製方法
ES2762864T3 (es) * 2008-06-18 2020-05-26 Oxford Biomedica Ltd Purificación de virus
CN102215865B (zh) 2008-09-24 2013-10-30 米迪缪尼有限公司 病毒纯化方法
WO2010060719A1 (en) * 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
CA2750055A1 (en) * 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
JP2010207800A (ja) * 2009-02-16 2010-09-24 Kuraray Co Ltd ろ過ユニットおよびこれを備えたろ過装置
JP2010193720A (ja) * 2009-02-23 2010-09-09 Asahi Kasei Chemicals Corp アニオン交換基が固定された多孔膜を用いたウイルスの分離方法
NZ596595A (en) 2009-05-12 2013-05-31 Transgene Sa Method for orthopoxvirus production and purification
US20120141980A1 (en) * 2009-08-17 2012-06-07 Merk Patent Gesellschaft Mit Beschrankter Haftung Method for isolating viruses
EP2488636B1 (de) 2009-10-15 2014-03-12 Crucell Holland B.V. Verfahren zur adenovirus-reinigung aus kulturen mit hoher zelldichte
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
EP2531592A1 (de) 2010-02-04 2012-12-12 Vivalis Fed-batch-verfahren mit konzentriertem zellkulturmedium zur effizienten produktion von biologischen wirkstoffen bei eb66-zellen
DK2536829T3 (en) 2010-02-15 2016-07-04 Crucell Holland Bv A process for the production of Ad26-adenovirus vectors
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US10087423B2 (en) 2010-07-20 2018-10-02 Bavarian Nordic A/S Method for harvesting expression products
SG188947A1 (en) * 2010-08-12 2013-06-28 Yisheng Biopharma Holdings Ltd Method for reducing dna impurities in viral compositions
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
WO2012069190A2 (en) * 2010-11-26 2012-05-31 Probiogen Ag Depletion of host cell components from live vector vaccines
CN103732610A (zh) * 2011-06-13 2014-04-16 默沙东公司 纯化天然或突变体形式的白喉毒素的方法
US10273462B2 (en) * 2011-07-27 2019-04-30 Vectalys Sas Virus-based vector compositions useful for transducing eukaryotic cells
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
KR102023791B1 (ko) 2012-03-22 2019-09-23 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CN103571800B (zh) * 2012-07-27 2018-04-24 江苏康润生物科技有限公司 一种去除疫苗中宿主dna的方法
RU2493872C1 (ru) * 2012-08-08 2013-09-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации ( ФГУП "НПО "Микроген" Минздрава России) Способ очистки вируса гриппа
CN103768589B (zh) * 2012-10-18 2016-12-21 辽宁成大生物股份有限公司 利用中空纤维膜去除人用乙型脑炎疫苗制品中残留dna的方法
AU2014222610A1 (en) * 2013-02-28 2015-10-15 Psioxus Therapuetics Limited A process for the production of adenovirus
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
KR20210054067A (ko) 2013-06-14 2021-05-12 싸이오서스 테라퓨틱스 엘티디. 유형 b 아데노바이러스에 대한 투여 요법 및 제형
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
AU2015294014B2 (en) * 2014-07-24 2018-08-23 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
DK3215187T3 (en) 2014-11-04 2018-12-10 Janssen Vaccines & Prevention Bv THERAPEUTIC HPV16 VACCINES
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
JP6886410B2 (ja) 2015-06-10 2021-06-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 核酸含有組成物の作製および精製のためのプロセス
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
AU2017259259B2 (en) 2016-05-02 2020-11-19 Bavarian Nordic A/S Therapeutic HPV vaccine combinations
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
EA039124B1 (ru) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
MX393584B (es) 2016-06-20 2025-03-21 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
EP3484506A1 (de) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv-impfstoffe
CN106434571A (zh) * 2016-10-19 2017-02-22 深圳源兴基因技术有限公司 一种wave无血清培养悬浮细胞制备重组腺病毒的方法
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
CN108085301B (zh) * 2016-11-22 2021-10-26 贺道耀 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
SG11201906271QA (en) 2017-02-09 2019-08-27 Janssen Vaccines & Prevention Bv Potent and short promoter for expression of heterologous genes
CN106868025B (zh) * 2017-03-13 2020-01-21 中国人民解放军军事医学科学院生物工程研究所 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
CN107603959A (zh) * 2017-08-30 2018-01-19 四川大学 提高缓冲液盐离子浓度纯化病毒的方法
JP2020533367A (ja) 2017-09-15 2020-11-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖに対する免疫の安全な誘導方法
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US11603527B2 (en) * 2017-12-27 2023-03-14 Global Life Sciences Solutions Usa Llc Method and kit for viral vector isolation
GB201814590D0 (en) * 2018-09-07 2018-10-24 Oxford Biomedica Ltd Viral vector production system
CN110317832B (zh) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
WO2019209632A1 (en) 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
AU2019286406B2 (en) 2018-06-12 2023-04-13 Kbio Holdings Limited Virus and antigen purification and conjugation
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
CN113330111A (zh) * 2018-11-21 2021-08-31 西方溶瘤细胞有限公司 病毒的制造
AU2020274632A1 (en) * 2019-05-14 2021-12-09 Janssen Biotech, Inc. Efficient impurity removal using a diafiltration process
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
CN114173827B (zh) * 2019-06-28 2025-01-28 武田药品工业株式会社 腺相关病毒纯化方法
CN111249456A (zh) * 2020-03-13 2020-06-09 武汉生物制品研究所有限责任公司 一种狂犬病病毒灭活疫苗的纯化方法
CN111394390A (zh) * 2020-03-26 2020-07-10 赛诺（深圳）生物医药研究有限公司 用于新型冠状病毒基因疫苗的批量生产重组腺病毒的方法
EP4200048A1 (de) * 2020-08-18 2023-06-28 Sartorius BIA Separations d.o.o. Metallaffinitätsextraktion von wirtszellen-dna
WO2022125793A1 (en) 2020-12-10 2022-06-16 Sarepta Therapeutics, Inc. Suspension mode seed train development for adherent cells
EP4341413A1 (de) 2021-05-17 2024-03-27 Sarepta Therapeutics, Inc. Herstellung rekombinanter aav-vektoren zur behandlung von muskeldystrophie
MX2024001860A (es) * 2021-08-10 2024-05-08 Biocon Ltd Purificacion de liraglutida.
CN113817689B (zh) * 2021-11-22 2023-10-03 北京艺妙神州医药科技有限公司 慢病毒纯化工艺
CA3246250A1 (en) * 2022-03-30 2023-10-05 Csl Behring Llc METHODS FOR PURIFYING AN ENVELOPED VIRUS
CN115807064A (zh) * 2022-07-20 2023-03-17 上海泰昶生物技术有限公司 重组腺相关病毒载体制品中游离和错误包装dna的检测方法
CN115141813A (zh) * 2022-07-29 2022-10-04 深圳源兴基因技术有限公司 一种高效去除宿主细胞残留蛋白的腺病毒纯化方法
CA3268452A1 (en) 2022-09-23 2024-03-28 Sarepta Therapeutics, Inc. RECOMMENDED AAV VECTORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
WO2024130163A1 (en) * 2022-12-16 2024-06-20 Avirmax Biopharma Inc. Methods for manufacturing viruses and viral particles

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434914B (sv) 1975-07-07 1984-08-27 Jonsson U R S Forfarande for att ur en suspension av bakterier och ett vetskeformigt medium genom filtrering avskilja mediet under samtidig anrikning av bakterierna
US4435289A (en) 1981-12-23 1984-03-06 Romicon, Inc. Series ultrafiltration with pressurized permeate
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US4808315A (en) 1986-04-28 1989-02-28 Asahi Kasei Kogyo Kabushiki Kaisha Porous hollow fiber membrane and a method for the removal of a virus by using the same
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP1548118A2 (de) * 1994-06-10 2005-06-29 Genvec, Inc. Komplementäre adenovirale Vektor-Systeme und Zelllinien
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) * 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) * 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
CZ438398A3 (cs) * 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ATE348155T1 (de) * 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
ES2273404T3 (es) 1997-01-31 2007-05-01 Schering Corporation Metodos para cultivar celulas y propagar virus.
US6168944B1 (en) * 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
EP0973866A4 (de) 1997-03-04 2000-04-19 Baxter Int Adenovirus e1-komplementierende zellinien
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5947689A (en) 1997-05-07 1999-09-07 Scilog, Inc. Automated, quantitative, system for filtration of liquids having a pump controller
CA2301000C (en) * 1997-08-28 2003-07-08 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
ES2290613T3 (es) 1998-02-17 2008-02-16 Schering Corporation Composiciones que comprenden virus y metodos para concentrar preparaciones de virus.
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
MXPA00010338A (es) * 1998-04-22 2005-06-17 Genvec Inc Purificacion eficiente de adenovirus.
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6342384B1 (en) * 1998-08-21 2002-01-29 The University Of Va Patent Foundation Production of adenoviral vectors using serum-free suspension cell culture in a hollow fiber system
WO2000029024A1 (en) 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU779267B2 (en) * 1998-12-31 2005-01-13 Centelion S.A.S. Method for separating viral particles
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
US6120820A (en) 1999-02-22 2000-09-19 Land O'lakes, Inc. Method of modifying the color of a dairy material
ATE364707T1 (de) 1999-05-17 2007-07-15 Crucell Holland Bv Rekombinanter humaner adenovirus-serotyp 35
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
DE10022258A1 (de) 2000-05-08 2001-11-15 Bayer Ag Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration
EP1320621A4 (de) 2000-09-15 2005-11-23 Merck & Co Inc Verbesserte adenovirale vakzine der ersten generation zur expression codon-optimierten hiv1-gag, pol, nef und modifikationen(25.03.02)
US6365395B1 (en) 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
JP4559026B2 (ja) 2001-03-01 2010-10-06 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 単一ユニット操作におけるアデノウイルス感染細胞の濃縮および溶解
JP2005508916A (ja) 2001-10-01 2005-04-07 アメリカ合衆国 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
WO2003049764A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
US20050118701A1 (en) 2002-03-29 2005-06-02 Weichang Zhou Large scale methods of producing adenovirus and adenovirus seed stocks
EP1497440B1 (de) 2002-04-25 2008-08-20 Crucell Holland B.V. Stabile adenovirale vektoren und methoden für deren vermehrung
CN100497639C (zh) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 生产腺病毒载体的手段和方法
DE60313451T2 (de) * 2002-05-14 2008-01-03 Merck & Co., Inc. Verfahren zur reinigung von adenovirus
US20050095705A1 (en) 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
WO2004112707A2 (en) * 2003-06-18 2004-12-29 Onyx Pharmaceuticals, Inc. Method for purifying virus
EP1780269B1 (de) 2004-02-23 2009-07-08 Crucell Holland B.V. Verfahren zur Reinigung von Viren
US20060078628A1 (en) * 2004-10-09 2006-04-13 Karl Koman Wound treating agent

Also Published As

Publication number Publication date
WO2005080556A2 (en) 2005-09-01
US8124106B2 (en) 2012-02-28
KR101211329B1 (ko) 2012-12-12
US20090017523A1 (en) 2009-01-15
NZ548495A (en) 2009-05-31
WO2005080556A3 (en) 2006-02-23
AU2005214090B2 (en) 2008-09-11
CA2555412A1 (en) 2005-09-01
EP1780269A2 (de) 2007-05-02
CA2555412C (en) 2013-06-25
DE602005015332D1 (de) 2009-08-20
KR20070001163A (ko) 2007-01-03
EP1780269A3 (de) 2007-07-18
CN101343625A (zh) 2009-01-14
JP2007522814A (ja) 2007-08-16
EP1718738A2 (de) 2006-11-08
WO2005080556A9 (en) 2006-10-26
EP1780269B1 (de) 2009-07-08
ES2329607T3 (es) 2009-11-27
US20070207461A1 (en) 2007-09-06
CN1922308A (zh) 2007-02-28
DK1780269T3 (da) 2009-10-12
AU2005214090A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
ATE435906T1 (de) Verfahren zur reinigung von viren
ATE446792T1 (de) Verfahren zur behandlung von sinuskopfschmerzen
EP1726599A4 (de) Verfahren zur herstellung von fluorpolymer
ATE431139T1 (de) Verfahren zur identifizierung von glp-1- sekretionsförderern
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
DE502004009763D1 (de) Verfahren zur herstellung von 1-buten
DE50307672D1 (de) Verfahren zur herstellung von polycarbonaten
DE602004010234D1 (de) Verfahren zur herstellung von 4-aminodiphenylamin
DE502004009768D1 (de) Verfahren zur herstellung von dreiwertigen organophosphor-verbindungen
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
DE60234952D1 (de) VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
DE60217096D1 (de) Verfahren zur herstellung von (s)-(+)- und (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepin-5-carboxamid
DE60328522D1 (de) Verfahren zur herstellung von bisphenol
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
DE502005010038D1 (de) Verfahren zur herstellung von 3-pentennitril
DE60302139D1 (de) Verfahren zur herstellung von aripiprazole
DE602004018249D1 (de) Verfahren zur Dearomatisierung von Molkeprotein
DE50310828D1 (de) Verfahren zur Reinigung von Spinneinrichtungen
ATE514673T1 (de) Verfahren zur trennung von pentennitril-isomeren
DE502004001216D1 (de) Verfahren zur aufreinigung von blausäure
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
DE502006002510D1 (de) Verfahren zur herstellung von silikon-haltigen polymerisaten
DE60226310D1 (de) Verfahren zur herstellung von cycloolefinadditionspolymerisat
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1780269

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1780269

Country of ref document: EP